Welcome to our dedicated page for Oragenics SEC filings (Ticker: OGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Oragenics Inc. filings document the regulatory record of a clinical-stage biotechnology company focused on intranasal CNS therapeutics. The company’s 8-K reports include clinical and regulatory disclosures for ONP-002, including materials related to its Phase IIa program for concussion and mild traumatic brain injury, along with Regulation FD presentations and other public updates.
The filing record also covers capital-structure matters such as at-the-market common stock sales arrangements, shareholder meeting and proposal deadlines, executive compensation and equity awards, governance matters, risk factors, operating results and financial-condition disclosures, including going-concern language in the annual report.
Oragenics Inc. reported that director Natasha Giordano received two stock option awards under the company’s 2021 Equity Incentive Plan on December 11, 2025. One non-employee director option covers 38,320 shares of common stock at an exercise price of $1.03, granted as an initial equity award upon her appointment to the board, and it vests immediately. A second option covers 125,000 shares at an exercise price of $0.93, also under the non-employee director compensation program, and it vests immediately as well. Both option grants are exercisable from December 11, 2025 and expire on December 11, 2035, and are held directly.
Oragenics Inc. director Fred Telling reported a small sale of company stock and a new stock option grant. On 12/12/2025, he sold 210 shares of common stock at a weighted average price of $0.9446 per share, leaving him with 34,538 shares of Oragenics common stock held directly.
On 12/11/2025, he received a non-employee director option award for 125,000 shares of Oragenics common stock under the company’s 2021 Equity Incentive Plan. The options have an exercise price of $0.93 per share, vest immediately on the grant date, and are scheduled to expire on 12/11/2035.
Oragenics Inc (OGEN) reported a grant of non-employee director stock options to director John Gandolfo. On 12/11/2025 he received options to purchase 125,000 shares of common stock at an exercise price of $ 0.93, with an expiration date of 12/11/2035.
The award was made under Oragenics' 2021 Equity Incentive Plan, as amended, pursuant to its non-employee director compensation program. The options vest immediately, and Gandolfo beneficially holds 125,000 derivative securities directly following this transaction.
Oragenics director Alan Dunton reported receiving an award of 125,000 options to buy the company’s common stock at an exercise price of $0.93 per share on 12/11/2025.
The options were granted under the company’s 2021 Equity Incentive Plan, as amended, pursuant to its non-employee director compensation program. They vest immediately, are exercisable starting 12/11/2025, and expire on 12/11/2035. Following this grant, 125,000 derivative securities are beneficially owned directly.
Oragenics Inc reported that director Robert Koski received a grant of stock options on 12/11/2025 under the company's 2021 Equity Incentive Plan, as amended, pursuant to its non-employee director compensation program. The option covers 125,000 shares of common stock at an exercise price of $0.93 per share, equal to the closing price on the grant date. The options vest immediately, are exercisable starting 12/11/2025, and expire on 12/11/2035. Following this award, Koski beneficially owns 125,000 stock options directly.
Oragenics Inc. reported that director Charles Pope received an award of stock options as part of the company’s non-employee director compensation program. On 12/11/2025 he was granted options to buy 125,000 shares of common stock at an exercise price of $0.93 per share under the company’s 2021 Equity Incentive Plan, as amended.
The options vest immediately, making them fully exercisable from the grant date, and they expire on 12/11/2035. After this grant, Pope beneficially owns 125,000 derivative securities directly, each representing the right to purchase one share of Oragenics common stock.
Oragenics, Inc. updated compensation for its leadership. The board increased Chief Executive Officer Janet Huffman’s annual base salary by five percent from $325,000 to $341,250, effective January 1, 2026, and awarded her a cash bonus of $110,500 based on performance under the existing compensation program.
The board also granted Huffman stock options to purchase 250,000 shares of common stock at an exercise price of $0.93 per share, vesting in equal annual installments over three years, with earlier vesting upon a change in control. Each non-employee director received options for 125,000 shares at $0.93 per share that vested immediately, and director Natasha Giordano received an additional onboarding stock option award valued at $30,000 when she joined the board.
A holder of OGEN common stock has filed a notice of proposed sale under Rule 144. The filing covers the planned sale of 210 shares of common stock through Goldman Sachs & Co. LLC on the NYSE, with an aggregate market value of 191.94. The shares relate to an issuer that had 4,168,223 shares outstanding at the time stated. The seller acquired 171 shares as restricted stock units on 06/17/2022 and 39 shares as restricted stock units on 11/20/2020, both described as compensation from the issuer.
Oragenics, Inc. filed a current report to note that it has issued a new press release for shareholders. On November 12, 2025, the company released an update describing recent developments that took place during the third quarter of 2025 and shortly afterward. The report states that this press release is being furnished as an exhibit and incorporated by reference, directing readers to that document for the detailed business and operational update.
Oragenics (OGEN) filed its Q3 2025 10‑Q, reporting a net loss of $3.07 million for the quarter and $7.56 million year‑to‑date. Operating expenses were driven by higher G&A tied to legal and financing activity, including a $700,000 accrual for a legal settlement, while R&D rose modestly as the company prepared ONP‑002 for clinical work.
Liquidity improved significantly: cash and equivalents were $11.4 million as of September 30, 2025, reflecting a July financing of $15.2 million in net proceeds from 660,000 Series H preferred shares and accompanying warrants, and repayment of a $3.0 million short‑term note. Stockholders’ equity stood at $9.83 million. The company effected a 1‑for‑30 reverse split in June and regained NYSE American equity compliance in October.
Management continues to note substantial doubt about the company’s ability to continue as a going concern, though current cash is expected to fund operations for at least the next twelve months and support the planned ONP‑002 Phase 2a start.